Sign In
Buy SUPN
$44.04
-0.0350 (-0.0794%)
At Close: Jun 03, 2026
Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a Year
06:41pm, Friday, 27'th Mar 2026
A Supernus Pharmaceuticals executive reported the sale of 107,250 Common Stock shares over three days for a total value of about $5.4 million. Bhatt reported holding 17,044 shares of directly owned co
Frederick Hudson Sells 5,369 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) Stock
05:00am, Wednesday, 18'th Mar 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) Director Frederick Hudson sold 5,369 shares of the business's stock in a transaction on Thursday, March 12th. The shares were sold at an
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
03:52pm, Wednesday, 11'th Mar 2026
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Victory Capital Management Inc.
04:23am, Tuesday, 10'th Mar 2026
Victory Capital Management Inc. decreased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 25.5% during the undefined quarter, according to its most recent filing with the Se
American Century Companies Inc. Decreases Position in Supernus Pharmaceuticals, Inc. $SUPN
03:03am, Monday, 09'th Mar 2026
American Century Companies Inc. trimmed its stake in Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 44.4% in the undefined quarter, according to its most recent filing with the Securities and Exchan
Bethany Sensenig Sells 4,475 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) Stock
04:44am, Wednesday, 25'th Feb 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) Director Bethany Sensenig sold 4,475 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, February 19th. The stock
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript
04:27am, Wednesday, 25'th Feb 2026
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
11:30pm, Tuesday, 24'th Feb 2026
While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compa
Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates
10:55pm, Tuesday, 24'th Feb 2026
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.75 per share a year ago.
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
04:05pm, Tuesday, 24'th Feb 2026
Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four g
Supernus Pharmaceuticals to Participate in March Investor Conferences
06:15pm, Monday, 23'rd Feb 2026
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline
11:01am, Tuesday, 17'th Feb 2026
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
04:35pm, Thursday, 12'th Feb 2026
ROCKVILLE, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Lunai Bioworks, Inc. Issues Letter to Shareholders
11:14am, Monday, 09'th Feb 2026
SACRAMENTO, Calif. , Feb. 9, 2026 /PRNewswire/ -- Dear Shareholders, We have completed our AI platform in the last 12 months and now it is commercial.
15,525 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by AdvisorShares Investments LLC
04:12am, Sunday, 08'th Feb 2026
AdvisorShares Investments LLC bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) during the undefined quarter, according to the company in its most recent Form 13F filing
